Students at Southwestern Middle School recently had the chance to show off their creative sides in a science fair for ...

IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, announced the submission of an ...

Discusses Year-End Late-Stage Pipeline Review With Focus on Clinical and Regulatory Developments December 16, 2025 11:15 AM ...

Consistent OS benefit in an Asian subset with a strong HR of 0.69 for non-squamous patients, and meaningful safety advantage position Plinabulin as a late-stage candidate showing survival improvement ...

November's wave of FDA oncology approvals signals the industry's shift toward platform-based precision therapies over broad-spectrum approaches([1]) . The global anticancer drug market now values ...

Track leadership turnover at the Texas Medical Center with our list including presidents from UTHealth, Baylor College of ...

Pharmanovia, a global pharmaceutical company that commercialises novel speciality medicines as well as trusted established medicines, has today announced the launch of catumaxomab in Germany, making ...

BeyondSpring (BYSI) announced results from the Asian subset of its global Phase 3 DUBLIN-3 trial evaluating Plinabulin plus docetaxel compared to ...

John Johnson, current board member, appointed to chairman of the boardMichael Kauffman, M.D., Ph.D., lead director since 2016, appointed to president of developmentCommercial launch progresses as RAMP ...

An experimental vaccine targeting aggressive triple-negative breast cancer (TNBC) has shown encouraging early results in ...

RESEARCH TRIANGLE PARK, N.C., Dec. 10, 2025 /PRNewswire/ -- Bantam Pharmaceutical, a clinical-stage company pioneering mitochondrial biology to develop first-in-class medicines for treating aggressive ...